2026-09-15T18:12:13Zhttps://gredos.usal.es/oai/request

oai:gredos.usal.es:10366/1616382025-04-30T19:35:22Zcom_10366_4019com_10366_3947com_10366_3946com_10366_3823col_10366_4020

Caravaca-Fontán, Fernando Stevens, Kate Padrón, Maite Huerta, Ana Montomoli, Marco Villa, Juan González, Fayna Vega, Cristina López Mendoza, Manuel Fernández, Loreto Shabaka, Amir Rodríguez-Moreno, Antolina Martín-Gómez, Adoración Labrador, Pedro J Molina Andújar, Alicia Prados Soler, M Carmen Martín-Penagos, Luis Yerovi, Estefanía Medina Zahonero, Laura De La Flor, José Carlos Mon, Carmen Ibernon, Meritxell Rodríguez Gómez, Astrid Miquel, Rosa Sierra, Milagros Mascarós, Victoria Luzardo, Leonella Papasotiriou, Marios Arroyo, David Verdalles, Úrsula Martínez-Miguel, Patricia Ramírez-Guerrero, Gonzalo Pampa-Saico, Saúl Moral Berrio, Esperanza Canga, José Luis Pérez Tarragón, Blanca Fraile Gómez, María Pilar Regidor, Dabaiba Relea, Javier Xipell, Marc Andrades Gómez, Cristina Navarro, Maruja Álvarez, Álvaro Rivas, Begoña Quintana, Luis F Gutiérrez, Eduardo Pérez-Valdivia, Miguel Ángel Odler, Balazs Kronbichler, Andreas Geddes, Colin Anders, Hans-Joachim Floege, Jürgen Fernández-Juárez, Gema Praga, Manuel 2025-01-13T09:13:16Z 2025-01-13T09:13:16Z 2023-08-07 Caravaca-Fontán, F., Stevens, K., Padrón, M., Huerta, A., Montomoli, M., Villa, J., González, F., Vega, C., López Mendoza, M., Fernández, L., Shabaka, A., Rodríguez-Moreno, A., Martín-Gómez, A., Labrador, P. J., Molina Andújar, A., Prados Soler, M. C., Martín-Penagos, L., Yerovi, E., Medina Zahonero, L., De La Flor, J. C., … Praga, M. (2024). Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 39(2), 328–340. https://doi.org/10.1093/ndt/gfad175 0931-0509 http://hdl.handle.net/10366/161638 10.1093/ndt/gfad175 37550217 1460-2385 [EN]The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation. Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by -35%, -41%, -45% and -48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by -6%, -3%, -8% and -10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30-0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: -3.7 versus -5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good. The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction. eng info:eu-repo/semantics/openAccess body mass index estimated glomerular filtration rate glomerular disease proteinuria Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. info:eu-repo/semantics/article